A KKR-led investor consortium has made an additional investment in Sylvan, a developer of fungal-based biotechnologies. The round also saw an increased ownership stake from existing investor Novo Holdings, signaling continued confidence in the company's platform.

This follow-on funding underscores the growing institutional interest in alternative protein and sustainable biotech sectors. Sylvan’s focus on mycelium-derived products aligns with market shifts toward climate-friendly agriculture and food innovation, areas where large funds are actively deploying capital.

The backing from a powerhouse like KKR provides Sylvan with both capital and strategic credibility. Investors will watch for the company’s next steps in commercializing its technology, potentially through partnerships with major food or ingredient manufacturers seeking sustainable solutions.